SITAHENZ D 50 TAB 10 S

About

SITAHENZ D 50 TAB likely combines Sitagliptin (50mg) and Dapagliflozin, offering a dual-mechanism approach for managing type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, works by increasing the levels of incretin hormones, which enhance insulin release and suppress glucagon secretion in a glucose-dependent manner, thereby lowering blood glucose. Dapagliflozin, an SGLT2 inhibitor, reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. This combination provides comprehensive glycemic control, addressing both insulin secretion and glucose elimination. Furthermore, dapagliflozin contributes significant cardiovascular and renal protective benefits, reducing the risk of heart failure hospitalization and progression of kidney disease, making this a robust option for patients needing multifaceted diabetes management.

Uses

• Management of type 2 diabetes mellitus
• Improvement of glycemic control
• Adjunct to diet and exercise
• Reduction of cardiovascular and renal risks

Directions For Use

Take orally once daily, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Comprehensive blood sugar control
• Supports weight reduction
• Reduces risk of major cardiovascular events
• Provides renal protective benefits
• Low risk of hypoglycemia (as monotherapy)
• Convenient once-daily combination therapy

Side Effects

• Urinary tract infections
• Genital yeast infections
• Nasopharyngitis
• Headache
• Increased urination
• Thirst
• Dehydration
• Nausea
• Diarrhea
• Abdominal pain
• Ketoacidosis (rare)
• Pancreatitis (rare)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of ketoacidosis, a serious side effect associated with SGLT2 inhibitors like dapagliflozin.
• Pregnancy - Not recommended during pregnancy. Consult your doctor immediately if you become pregnant or plan to conceive.
• Breastfeeding - Not recommended during breastfeeding as the components may pass into breast milk. Consult your doctor.
• Liver - Use with caution in patients with severe hepatic impairment; data for dapagliflozin in this population is limited.
• Kidney - Dose adjustment for sitagliptin is required in renal impairment. Dapagliflozin's efficacy for glycemic control decreases with declining renal function, but it is indicated for CKD progression.
• Lung - No specific direct lung contraindication.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.